Methylene blue modulates β-secretase, reverses cerebral amyloidosis, and improves cognition in transgenic mice

Journal of Biological Chemistry

Volumn 289, Issue 44, 2014, Pages 30303-30317

  Mori, Takashi ^a   Koyama, Naoki ^a   Segawa, Tatsuya ^b   Maeda, Masahiro ^b   Maruyama, Nobuhiro ^b   Kinoshita, Noriaki ^b   Hou, Huayan ^c   Tan, Jun ^c,d   Town, Terrence ^e  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b Immuno Biological Laboratories Co Ltd   (Japan)

^c Silver Child Development Center   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC COMPOUNDS; BRAIN; DISEASES; GLYCOPROTEINS; MAMMALS; OBJECT RECOGNITION; PATHOLOGY; PROTEOLYSIS;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEINS; CARBOXYL-TERMINAL; CEREBRAL AMYLOID; CHINESE HAMSTER OVARY CELLS; COGNITIVE FUNCTIONS; METHEMOGLOBINEMIA; PROTEIN EXPRESSIONS;

PROTEINS;

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; METHYLENE BLUE; OLIGOMER; SECRETASE;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHO CELL LINE; COGNITION; CONTROLLED STUDY; ENZYME ACTIVITY; HYPERACTIVITY; MALE; METHEMOGLOBINEMIA; MOUSE; NEUROMODULATION; NONHUMAN; OBJECT RELATION; PATTERN RECOGNITION; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REFERENCE MEMORY; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; BRAIN CORTEX; BRAIN DISEASES; C57BL MOUSE; CRICETULUS; DRUG EFFECTS; DRUG SCREENING; HAMSTER; HUMAN; MAZE TEST; METABOLISM; PATHOLOGY; PSYCHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; AMYLOIDOSIS; ANIMALS; BRAIN DISEASES; CEREBRAL CORTEX; CHO CELLS; COGNITION; CRICETINAE; CRICETULUS; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; MAZE LEARNING; METHYLENE BLUE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTEOLYSIS;

EID: 84910026958     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.568212     Document Type: Article

References (86)

1. Brookmeyer, R., and Gray, S. (2000) Methods for projecting the incidence and prevalence of chronic diseases in aging populations: application to Alzheimer's disease. Stat. Med. 19, 1481-1493
2. Selkoe, D. J. (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766
3. Alzheimer's Disease International (2012) Overcoming the Stigma of Dementia, World Alzheimer Report 2012. Alzheimer's Disease International, London
4. Rozemuller, J. M., Eikelenboom, P., Stam, F. C., Beyreuther, K., and Masters, C. L. (1989) A4 protein in Alzheimer's disease: primary and secondary cellular events in extracellular amyloid deposition. J. Neuropathol. Exp. Neurol. 48, 674-691
5. Hardy, J., and Allsop, D. (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12, 383-388
6. Bates, K. A., Verdile, G., Li, Q. X., Ames, D., Hudson, P., Masters, C. L., and Martins, R. N. (2009) Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests. Mol. Psychiatry 14, 469-486
7. Gravitz, L. (2011) Drugs: a tangled web of targets. Nature 475, S9-S11
8. Oz, M., Lorke, D. E., Hasan, M., and Petroianu G. A. (2011) Cellular and molecular actions of methylene blue in the nervous system. Med. Res. Rev. 31, 93-117
9. Schirmer, R. H., Adler, H., Pickhardt, M., and Mandelkow, E. (2011) "Lest we forget you-methylene blue..." Neurobiol. Aging 32, 2325. e7-16
10. Klamer, D., Engel, J. A., and Svensson, L. (2004) Phencyclidine-induced behaviour in mice prevented by methylene blue. Basic Clin. Pharmacol. Toxicol. 94, 65-72
11. Riha, P. D., Bruchey, A. K., Echevarria, D. J., and Gonzalez-Lima, F. (2005) Memory facilitation by methylene blue: dose-dependent effect on behavior and brain oxygen consumption. Eur. J. Pharmacol. 511, 151-158
12. Narsapur, S. L., and Naylor, G. J. (1983) Methylene blue. A possible treatment for manic depressive psychosis. J. Affect. Disord. 5, 155-161
13. Naylor, G. J., Martin, B., Hopwood, S. E., and Watson, Y. (1986) A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis. Biol. Psychiatry 21, 915-920
14. Deiana, S., Harrington, C. R., Wischik, C. M., and Riedel, G. (2009) Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. Psychopharmacology (Berl) 202, 53-65
15. Gura, T. (2008) Hope in Alzheimer's fight emerges from unexpected places. Nat. Med. 14, 894
16. Wischik, C., Staff, R. (2009) Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy. J. Nutr. Health Aging 13, 367-369
17. Borchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., and Sisodia, S. S. (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19, 939-945
18. Garcia-Alloza, M., Robbins, E. M., Zhang-Nunes, S. X., Purcell, S. M., Betensky, R. A., Raju, S., Prada, C., Greenberg, S. M., Bacskai, B. J., and Frosch, M. P. (2006) Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 24, 516-524
19. Hahn, S., Brüning, T., Ness, J., Czirr, E., Baches, S., Gijsen, H., Korth, C., Pietrzik, C. U., Bulic, B., and Weggen, S. (2011) Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to γ-secretase modulators regardless of their potency and structure. J. Neurochem. 116, 385-395
20. Arendash, G. W., King, D. L., Gordon, M. N., Morgan, D., Hatcher, J. M., Hope, C. E., and Diamond, D. M. (2001) Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res. 891, 42-53
21. Jankowsky, J. L., Slunt, H. H., Gonzales, V., Jenkins, N. A., Copeland, N. G., and Borchelt, D. R. (2004) APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1. Neurobiol. Aging 25, 885-892
22. Mori, T., Rezai-Zadeh, K., Koyama, N., Arendash, G. W., Yamaguchi, H., Kakuda, N., Horikoshi-Sakuraba, Y., Tan, J., and Town, T. (2012) Tannic acid is a natural β-secretase inhibitor that prevents cognitive impairment and mitigates Alzheimer-like pathology in transgenic mice. J. Biol. Chem. 287, 6912-6927
23. Mori, T., Koyama, N., Guillot-Sestier, M. V., Tan, J., and Town, T. (2013) Ferulic acid is a nutraceutical β-secretase modulator that improves behavioral impairment and Alzheimer-like pathology in transgenic mice. PLoS ONE 8, e55774
24. Laghmouch, A., Bertholet, J. Y., and Crusio, W. E. (1997) Hippocampal morphology and open-field behavior in Mus musculus domesticus and Mus spretus inbred mice. Behav. Genet. 27, 67-73
25. Kim, K. S., and Han, P. L. (2006) Optimization of chronic stress paradigms using anxiety- and depression-like behavioral parameters. J. Neurosci. Res. 83, 497-507
26. Town, T., Laouar, Y., Pittenger, C., Mori, T., Szekely, C. A., Tan, J., Duman, R. S., and Flavell, R. A. (2008) Blocking TGF-β-Smad2β innate immune signaling mitigates Alzheimer-like pathology. Nat. Med. 14, 681-687
27. De Rosa, R., Garcia, A. A., Braschi, C., Capsoni, S., Maffei, L., Berardi, N., and Cattaneo, A. (2005) Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 102, 3811-3816
28. Alamed, J., Wilcock, D. M., Diamond, D. M., Gordon, M. N., and Morgan, D. (2006) Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. NatProtoc. 1, 1671-1679
29. Franklin, K. B. J., and Paxinos, G. (2001) The Mouse Brain in Stereotaxic Coordinates, Academic Press, San Diego
30. Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., and Younkin, S. G. (2001) Age-dependent changes in brain, CSF, and plasma amyloid (β) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21, 372-381
31. Jankowsky, J. L., Slunt, H. H., Gonzales, V., Savonenko, A. V., Wen, J. C., Jenkins, N. A., Copeland, N. G., Younkin, L. H., Lester, H. A., Younkin, S. G., and Borchelt, D. R. (2005) Persistent amyloidosis following suppression of Aβ production in a transgenic model of Alzheimer disease. PLoS Med. 2, e355
32. Horikoshi, Y., Sakaguchi, G., Becker, A. G., Gray, A. J., Duff, K., Aisen, P. S., Yamaguchi, H., Maeda, M., Kinoshita, N., and Matsuoka, Y. (2004) Development of Aβ terminal end-specific antibodies and sensitive ELISA for Aβ variant. Biochem. Biophys. Res. Commun. 319, 733-737
33. Xia, W., Yang, T., Shankar, G., Smith, I. M., Shen, Y., Walsh, D. M., and Selkoe, D. J. (2009) A specific enzyme-linked immunosorbent assay for measuring β-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch. Neurol. 66, 190-199
34. Monney, L., Sabatos, C. A., Gaglia, J. L., Ryu, A., Waldner, H., Chernova, T., Manning, S., Greenfield, E. A., Coyle, A. J., Sobel, R. A., Freeman, G. J., and Kuchroo, V. K. (2002) Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415, 536-541
35. King, D. L., Arendash, G. W., Crawford, F., Sterk, T., Menendez, J., and Mullan, M. J. (1999) Progressive and gender-dependent cognitive impairment in the APPSW transgenic mouse model for Alzheimer's disease. Behav. Brain Res. 103, 145-162
36. Mori, T., Town, T., Tan, J., Yada, N., Horikoshi, Y., Yamamoto, J., Shimoda, T., Kamanaka, Y., Tateishi, N., and Asano, T. (2006) Arundic acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice. J. Pharmacol. Exp. Ther. 318, 571-578
37. Mori, T., Koyama, N., Arendash, G. W., Horikoshi-Sakuraba, Y., Tan, J., and Town, T. (2010) Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease. Glia 58, 300-314
38. Ellis, R. J., Olichney, J. M., Thal, L. J., Mirra, S. S., Morris, J. C., Beekly, D., and Heyman, A. (1996) Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 46, 1592-1596
39. DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., and Holtzman, D. M. (2002) Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264-2267
40. De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., and Van Leuven, F. (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387-390
41. Sinha, S., and Lieberburg, I. (1999) Cellular mechanisms of β-amyloid production and secretion. Proc. Natl. Acad. Sci. U. S. A. 96, 11049-11053
42. Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski, M. A., Biere, A. L., Curran, E., Burgess, T., Louis, J. C., Collins, F., Treanor, J., Rogers, G., and Citron, M. (1999) β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741
43. Vassar, R., Kovacs, D. M., Yan, R., and Wong, P. C (2009) The β-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J. Neurosci. 29, 12787-12794
44. Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashier, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., Carter, D. B., Tomasselli, A. G., Parodi, L. A., Heinrikson, R. L., and Gurney, M. E. (1999) Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity. Nature 402, 533-537
45. Buchholz, K., Schirmer, R. H., Eubel, J. K., Akoachere, M. B., Dandekar, T., Becker, K., and Gromer, S. (2008) Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum. Antimicrob. Agents Chemother. 52, 183-191
46. Harvey, B. H., Duvenhage, I., Viljoen, F., Scheepers, N., Malan, S. F., Wegener, G., Brink, C. B., and Petzer, J. P. (2010) Role of monoamine oxidase, nitric oxide synthase and regional brain monoamines in the antidepressant-like effects of methylene blue and selected structural analogues. Biochem. Pharmacol. 80, 1580-1591
47. Clifton, J., 2nd, and Leikin, J. B. (2003) Methylene blue. Am. J. Ther. 10, 289-291
48. Barnes, D. G., and Dourson, M. (1988) Reference dose (RfD): description and use in health risk assessments. Regul. Toxicol. Pharmacol. 8, 471-486
49. Dourson, M. L., Felter, S. P., and Robinson, D. (1996) Evolution of sciencebased uncertainty factors in noncancer risk assessment. Regul. Toxicol. Pharmacol. 24, 108-120
50. Peter, C., Hongwan, D., Küpfer, A., and Lauterburg, B. H. (2000) Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur. J. Clin. Pharmacol. 56, 247-250
51. Walter-Sack, I., Rengelshausen, J., Oberwittler, H., Burhenne, J., Mueller, O., Meissner, P., and Mikus, G. (2009) High absolute bioavailability of methylene blue given as an aqueous oral formulation. Eur. J. Clin. Pharmacol. 65, 179-189
52. DiSanto, A. R., and Wagner, J. G. (1972) Pharmacokinetics of highly ionized drugs. II. Methylene blue-absorption, metabolism, and excretion in man and dog after oral administration. J. Pharm. Sci. 61, 1086-1090
53. Müller, T. (1998) Methylene blue supravital staining: an evaluation of its applicability to the mammalian brain and pineal gland. Histol. Histopathol. 13, 1019-1026
54. Medina, D. X., Caccamo, A., and Oddo, S. (2011) Methylene blue reduces Aβ levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol. 21, 140-149
55. Paban, V., Manrique, C., Filali, M., Maunoir-Regimbal, S., Fauvelle, F., and Alescio-Lautier, B. (2014) Therapeutic and preventive effects of methylene blue on Alzheimer's disease pathology in a transgenic mouse model. Neuropharmacology 76, 68-79
56. Nordberg, A. (2006) Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 20, S12-S18
57. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vandevert, C., Walker, S., Wogulis, M., Yednock, T., Games, D., and Seubert, P. (1999) Immunization with amyloid-β attenuates Alzheimerdisease-like pathology in the PDAPP mouse. Nature 400, 173-177
58. Kotilinek, L. A., Bacskai, B., Westerman, M., Kawarabayashi, T., Younkin, L., Hyman, B. T., Younkin, S., and Ashe, K. H. (2002) Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22, 6331-6335
59. Mouri, A., Noda, Y., Hara, H., Mizoguchi, H., Tabira, T., and Nabeshima, T. (2007) Oral vaccination with a viral vector containing Aβ cDNA attenuates age-related Aβ accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEBJ. 21, 2135-2148
60. Holcomb, L. A., Gordon, M. N., Jantzen, P., Hsiao, K., Duff, K., and Morgan, D. (1999) Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav. Genet. 29, 177-185
61. Westerman, M. A., Cooper-Blacketer, D., Mariash, A., Kotilinek, L., Kawarabayashi, T., Younkin, L. H., Carlson, G. A., Younkin, S. G., and Ashe, K. H. (2002) The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22, 1858-1867
62. Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., and Selkoe, D. J. (2002) Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539
63. Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., and Ashe, K. H. (2005) Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat Neurosci. 8, 79-84
64. Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., Regan, C. M., Walsh, D. M., Sabatini, B. L., and Selkoe, D. J. (2008) Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842
65. Necula, M., Breydo, L., Milton, S., Kayed, R., van der Veer, W. E., Tone, P., and Glabe, C. G. (2007) Methylene blue inhibits amyloid Aβ oligomerization by promoting fibrillization. Biochemistry 46, 8850-8860
66. Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., and Ashe, K. H. (2006) A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352-357
67. Wischik, C. M., Edwards, P. C., Lai, R. Y., Roth, M., and Harrington, C. R. (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc. Natl. Acad. Sci. U. S. A. 93, 11213-11218
68. Taniguchi, S., Suzuki, N., Masuda, M., Hisanaga, S., Iwatsubo, T., Goedert, M., and Hasegawa, M. (2005) Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280, 7614-7623
69. van Bebber, F., Paquet, D., Hruscha, A., Schmid, B., and Haass, C. (2010) Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish. Neurobiol. Dis. 39, 265-271
70. Congdon, E. E., Wu, J. W., Myeku, N., Figueroa, Y. H., Herman, M., Marinec, P. S., Gestwicki, J. E., Dickey, C. A., Yu, W. H., and Duff, K. E. (2012) Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy 8, 609-622
71. Hosokawa, M., Arai, T., Masuda-Suzukake, M., Nonaka, T., Yamashita, M., Akiyama, H, and Hasegawa, M. (2012) Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice. PLoS ONE 7, e52389
72. Gandhi, S., Refolo, L. M., and Sambamurti, K. (2004) Amyloid precursor protein compartmentalization restricts β-amyloid production: therapeutic targets based on BACE compartmentalization. J. Mol. Neurosci. 24, 137-143
73. Lichtenthaler, S. F., Dominguez, D. I., Westmeyer, G. G., Reiss, K., Haass, C., Saftig, P., De Strooper, B., and Seed, B. (2003) The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J. Biol. Chem. 278, 48713-48719
74. Li, Q., and Südhof, T. C. (2004) Cleavage of amyloid-β precursor protein and amyloid-β precursor-like protein by BACE 1. J. Biol. Chem. 279, 10542-10550
75. Pastorino, L., Ikin, A. F., Lamprianou, S., Vacaresse, N., Revelli, J. P., Platt, K., Paganetti, P., Mathews, P. M., Harroch, S., and Buxbaum, J. D. (2004) BACE (β-secretase) modulates the processing of APLP2 in vivo. Mol. Cell Neurosci. 25, 642-649
76. von Arnim, C. A., Kinoshita, A., Peltan, I. D., Tangredi, M. M., Herl, L., Lee, B. M., Spoelgen, R., Hshieh, T. T., Ranganathan, S., Battey, F. D., Liu, C. X., Bacskai, B. J., Sever, S., Irizarry, M. C., Strickland, D. K., and Hyman B. T. (2005) The low density lipoprotein receptor-related protein (LRP) is a novel β-secretase (BACE1) substrate. J. Biol. Chem. 280, 17777-17785
77. Wong, H. K., Sakurai, T., Oyama, F., Kaneko, K., Wada, K., Miyazaki, H., Kurosawa, M., De Strooper, B., Saftig, P., and Nukina, N. (2005) β subunits of voltage-gated sodium channels are novel substrates of β-site amyloid precursor protein-cleaving enzyme (BACE1) and 7-secretase. J. Biol. Chem. 280, 23009-23017
78. Willem, M., Garratt, A. N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., DeStrooper, B., Saftig, P., Birchmeier, C, and Haass, C (2006) Control of peripheral nerve myelination by the β-secretase BACE1. Science 314, 664-666
79. Hu, X., He, W., Diaconu, C., Tang, X., Kidd, G. J., Macklin, W. B., Trapp, B. D., and Yan, R. (2008) Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. FASEB J. 22, 2970-2980
80. Luo, Y., Bolon, B., Kahn, S., Bennett, B. D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., Martin, L., Louis, J. C., Yan, Q., Richards, W. G., Citron, M., and Vassar, R. (2001) Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation. Nat. Neurosci. 4, 231-232
81. Ohno, M., Sametsky, E. A., Younkin, L. H., Oakley, H., Younkin, S. G., Citron, M., Vassar, R., and Disterhoft, J. F. (2004) BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 41, 27-33
82. Nishitomi, K., Sakaguchi, G., Horikoshi, Y., Gray, A. J., Maeda, M., Hirata-Fukae, C., Becker, A. G., Hosono, M., Sakaguchi, I., Minami, S. S., Nakajima, Y., Li, H. F., Takeyama, C., Kihara, T., Ota, A., Wong, P. C., Aisen, P. S., Kato, A., Kinoshita, N, and Matsuoka, Y. (2006) BACE1 inhibition reduces endogenous Aβ and alters APP processing in wild-type mice. J. Neurochem. 99, 1555-1563
83. Wang, H., Song, L., Lee, A., Laird, F., Wong, P. C, and Lee, H. K. (2010) Mossy fiber long-term potentiation deficits in BACE1 knock-outs can be rescued by activation of a7 nicotinic acetylcholine receptors. J. Neurosci. 30, 13808-13813
84. Cai, J., Qi, X., Kociok, N., Skosyrski, S., Emilio, A., Ruan, Q., Han, S., Liu, L., Chen, Z., Bowes Rickman, C., Golde, T., Grant, M. B., Saftig, P., Serneels, L., de Strooper, B., Joussen, A. M., and Boulton, M. E. (2012) β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. EMBO Mol. Med. 4, 980-991
85. Hitt, B., Riordan, S. M., Kukreja, L., Eimer, W. A., Rajapaksha, T. W., and Vassar, R. (2012) β-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects. J. Biol. Chem. 287, 38408-38425
86. Yan, R., and Vassar, R. (2014) Targeting the β secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 13, 319-329